These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Choon SE; Lai NM; Mohammad NA; Nanu NM; Tey KE; Chew SF Int J Dermatol; 2014 Jun; 53(6):676-84. PubMed ID: 23967807 [TBL] [Abstract][Full Text] [Related]
69. Treatment of pustular psoriasis with infliximab. Weishaupt C; Metze D; Luger TA; Ständer S J Dtsch Dermatol Ges; 2007 May; 5(5):397-9. PubMed ID: 17451384 [TBL] [Abstract][Full Text] [Related]
70. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies. Rallis E; Verros CD Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089 [No Abstract] [Full Text] [Related]
71. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. Nijsten T; Margolis DJ; Feldman SR; Rolstad T; Stern RS J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):434-44. PubMed ID: 15761421 [TBL] [Abstract][Full Text] [Related]
72. Additive effects of calcipotriol and cyclosporine A: from in vitro experiments to in vivo applications in the treatment of severe psoriasis. Bagot M; Grossman R; Pamphile R; Binderup L; Charue D; Revuz J; Dubertret L C R Acad Sci III; 1994 Mar; 317(3):282-6. PubMed ID: 7994616 [TBL] [Abstract][Full Text] [Related]
74. Vitamin D and systemic therapy. van de Kerkhof P Cutis; 2002 Nov; 70(5 Suppl):16-20. PubMed ID: 12467335 [TBL] [Abstract][Full Text] [Related]
75. Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist. Sugiura K; Endo K; Akasaka T; Akiyama M J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2054-6. PubMed ID: 24910924 [No Abstract] [Full Text] [Related]
76. Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010. Akasaka E; Mabuchi T; Manabe Y; Yahagi E; Yamada-Hiruma A; Yamaoka H; Kojima T; Kato M; Ikoma N; Ozawa A; Haruki Y J Dermatol; 2013 Apr; 40(4):238-43. PubMed ID: 23330814 [TBL] [Abstract][Full Text] [Related]
77. How are we using systemic drugs to treat psoriasis in children? An insight into current clinical U.K. practice. Burden-Teh E; Lam ML; Taibjee SM; Taylor A; Webster S; Dolman S; Jury C; Caruana D; Darne S; Carmichael A; Natarajan S; McPherson T; Moore A; Katugampola R; Kalavala M; Al-Ismail D; Richards L; Jones V; Batul Syed S; Glover M; Hughes J; Anderson E; Hughes B; Helbling I; Murphy R Br J Dermatol; 2015 Aug; 173(2):614-8. PubMed ID: 25601323 [No Abstract] [Full Text] [Related]
78. Biologic therapy in erythrodermic and pustular psoriasis. Levin EC; Debbaneh M; Koo J; Liao W J Drugs Dermatol; 2014 Mar; 13(3):342-54. PubMed ID: 24595581 [TBL] [Abstract][Full Text] [Related]
79. Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A. Schopf RE; Hultsch T; Lotz J; Bräutigam M J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):234-9. PubMed ID: 9883435 [TBL] [Abstract][Full Text] [Related]
80. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). Sánchez-Regaña M; Sola-Ortigosa J; Alsina-Gibert M; Vidal-Fernández M; Umbert-Millet P J Eur Acad Dermatol Venereol; 2011 May; 25(5):579-86. PubMed ID: 21198950 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]